| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Corixa Corp. and
Infectious Disease Research Institute, Seattle, WA 98104;
Colorado State University, Fort Collins, CO 80523; and
GlaxoSmithKline Biologicals, Rixensart, Belgium
Key Ags of Mycobacterium tuberculosis initially identified in the context of host responses in healthy purified protein derivative-positive donors and infected C57BL/6 mice were prioritized for the development of a subunit vaccine against tuberculosis. Our lead construct, Mtb72F, codes for a 72-kDa polyprotein genetically linked in tandem in the linear order Mtb32C-Mtb39-Mtb32N. Immunization of C57BL/6 mice with Mtb72F DNA resulted in the generation of IFN-
responses directed against the first two components of the polyprotein and a strong CD8+ T cell response directed exclusively against Mtb32C. In contrast, immunization of mice with Mtb72F protein formulated in the adjuvant AS02A resulted in the elicitation of a moderate IFN- response and a weak CD8+ T cell response to Mtb32c. However, immunization with a formulation of Mtb72F protein in AS01B adjuvant generated a comprehensive and robust immune response, resulting in the elicitation of strong IFN- and Ab responses encompassing all three components of the polyprotein vaccine and a strong CD8+ response directed against the same Mtb32C epitope identified by DNA immunization. All three forms of Mtb72F immunization resulted in the protection of C57BL/6 mice against aerosol challenge with a virulent strain of M. tuberculosis. Most importantly, immunization of guinea pigs with Mtb72F, delivered either as DNA or as a rAg-based vaccine, resulted in prolonged survival (>1 year) after aerosol challenge with virulent M. tuberculosis comparable to bacillus Calmette-Guérin immunization. Mtb72F in AS02A formulation is currently in phase I clinical trial, making it the first recombinant tuberculosis vaccine to be tested in humans.
This article has been cited by other articles:
|
|
 |
|
  S. G. Reed, R. N. Coler, W. Dalemans, E. V. Tan, E. C. DeLa Cruz, R. J. Basaraba, I. M. Orme, Y. A. W. Skeiky, M. R. Alderson, K. D. Cowgill, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys PNAS, February 17, 2009; 106(7): 2301 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bertholet, G. C. Ireton, M. Kahn, J. Guderian, R. Mohamath, N. Stride, E. M. Laughlin, S. L. Baldwin, T. S. Vedvick, R. N. Coler, et al. Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis J. Immunol., December 1, 2008; 181(11): 7948 - 7957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, J. S. Woodworth, D. S. Shin, S. Morris, and S. M. Behar Vaccine-Elicited 10-Kilodalton Culture Filtrate Protein-Specific CD8+ T Cells Are Sufficient To Mediate Protection against Mycobacterium tuberculosis Infection Infect. Immun., May 1, 2008; 76(5): 2249 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hebert, S. Talarico, D. Yang, R. Durmaz, C. F. Marrs, L. Zhang, B. Foxman, and Z. Yang DNA Polymorphisms in the pepA and PPE18 Genes among Clinical Strains of Mycobacterium tuberculosis: Implications for Vaccine Efficacy Infect. Immun., December 1, 2007; 75(12): 5798 - 5805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Wang, M. Henao-Tamayo, M. Harton, D. Ordway, C. Shanley, R. J. Basaraba, and I. M. Orme A Toll-Like Receptor-2-Directed Fusion Protein Vaccine against Tuberculosis Clin. Vaccine Immunol., July 1, 2007; 14(7): 902 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doi, H. Yamada, T. Yajima, W. Wajjwalku, T. Hara, and Y. Yoshikai H2-M3-Restricted CD8+ T Cells Induced by Peptide-Pulsed Dendritic Cells Confer Protection against Mycobacterium tuberculosis J. Immunol., March 15, 2007; 178(6): 3806 - 3813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Alderson, P. McGowan, J. R. Baldridge, and P. Probst TLR4 agonists as immunomodulatory agents Innate Immunity, October 1, 2006; 12(5): 313 - 319. [Abstract] [PDF]
|
|
|
|
|
|
A. S. Mustafa, Y. A. Skeiky, R. Al-Attiyah, M. R. Alderson, R. G. Hewinson, and H. M. Vordermeier Immunogenicity of Mycobacterium tuberculosis Antigens in Mycobacterium bovis BCG-Vaccinated and M. bovis-Infected Cattle. Infect. Immun., August 1, 2006; 74(8): 4566 - 4572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Ha, S.-H. Park, H.-J. Kim, S.-C. Kim, H.-J. Kang, E.-G. Lee, S.-G. Kwon, B.-M. Kim, S.-H. Lee, W.-B. Kim, et al. Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination. Infect. Immun., August 1, 2006; 74(8): 4954 - 4959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tsenova, R. Harbacheuski, A. L. Moreira, E. Ellison, W. Dalemans, M. R. Alderson, B. Mathema, S. G. Reed, Y. A. W. Skeiky, and G. Kaplan Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis Infect. Immun., April 1, 2006; 74(4): 2392 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty and P. Andersen Vaccines for Tuberculosis: Novel Concepts and Recent Progress Clin. Microbiol. Rev., October 1, 2005; 18(4): 687 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Irwin, A. A. Izzo, S. W. Dow, Y. A. W. Skeiky, S. G. Reed, M. R. Alderson, and I. M. Orme Tracking Antigen-Specific CD8 T Lymphocytes in the Lungs of Mice Vaccinated with the Mtb72F Polyprotein Infect. Immun., September 1, 2005; 73(9): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Shin, C.-F. Chang, C.-D. Chang, S. P. McDonough, B. Thompson, H. S. Yoo, and Y.-F. Chang In Vitro Cellular Immune Responses to Recombinant Antigens of Mycobacterium avium subsp. paratuberculosis Infect. Immun., August 1, 2005; 73(8): 5074 - 5085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Taylor, D. J. Ordway, J. Troudt, M. Gonzalez-Juarrero, R. J. Basaraba, and I. M. Orme Factors Associated with Severe Granulomatous Pneumonia in Mycobacterium tuberculosis-Infected Mice Vaccinated Therapeutically with hsp65 DNA Infect. Immun., August 1, 2005; 73(8): 5189 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Martin The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur. Respir. J., July 1, 2005; 26(1): 162 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsumoto, M. Matsumoto, K. Umemori, Y. Ozeki, M. Furugen, T. Tatsuo, Y. Hirayama, S. Yamamoto, T. Yamada, and K. Kobayashi DNA Augments Antigenicity of Mycobacterial DNA-Binding Protein 1 and Confers Protection against Mycobacterium tuberculosis Infection in Mice J. Immunol., July 1, 2005; 175(1): 441 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Reece, N. Stride, P. Ovendale, S. G. Reed, and A. Campos-Neto Skin Test Performed with Highly Purified Mycobacterium tuberculosis Recombinant Protein Triggers Tuberculin Shock in Infected Guinea Pigs Infect. Immun., June 1, 2005; 73(6): 3301 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. Aldwell, L. Brandt, C. Fitzpatrick, and I. M. Orme Mice Fed Lipid-Encapsulated Mycobacterium bovis BCG Are Protected against Aerosol Challenge with Mycobacterium tuberculosis Infect. Immun., March 1, 2005; 73(3): 1903 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Brandt, Y. A. W. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, et al. The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis-Infected Guinea Pigs Infect. Immun., November 1, 2004; 72(11): 6622 - 6632. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
